From: Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
Pharmacy | Consultation (GP/specialist) | Nursing care | Total ambulatory care costs | ||
---|---|---|---|---|---|
Monotherapy (N = 411) | m (σ) | 1,798 (2,433) | 307 (252) | 143 (683) | 4,226 (5,369) |
Increase rate vs NRF | 56% | 20% | 0% | 40% | |
Double therapy (N = 267) | m (σ) | 1,893 (3,908) | 301 (171) | 210 (963) | 4,159 (5,268) |
Cost ratio vs mono (%) | 1.094* | 0.978 | 0.736 | 0.959 | |
Increase rate vs NRF | 34% | 21% | 38% | 26% | |
Triple therapy (N = 78) | m (σ) | 2,141 (3,056) | 305 (152) | 99 (504) | 4,032 (4,329) |
Cost ratio vs mono (%) | 1.262 *** | 1.029 | 0.903 | 1.031 | |
Increase rate vs NRF | 19% | 17% | 5% | 12% | |
Insulin therapy (N = 267) | m (σ) | 3,889 (5,363) | 422 (340) | 2,161 (3,638) | 11,344 (11,185) |
Cost ratio vs mono (%) | 2.020 *** | 1.230 *** | 10.236 *** | 2.223*** | |
Increase rate vs NRF | 47% | 28% | 36% | 53% |